TPXimpact Upgrades EBITDA Guidance to £7M+ as New Business Hits £110M

TPXimpact Q3 trading update: EBITDA guidance nudged up and sales momentum builds

TPXimpact Holdings (AIM: TPX) has upgraded its full-year adjusted EBITDA guidance to not less than £7.0 million for FY26 after a strong Q3 to 31 December 2025 and continued momentum into Q4. Net debt is guided to come in below £6.0 million, with leverage around 0.85x net debt to EBITDA. Year to date, new business signed has topped £110 million, anchored by sizeable UK public sector wins.

Management says the three-year turnaround plan has been successfully concluded, with profitability and debt trending the right way. A fresh three-year growth plan is being finalised for FY27 onward, alongside a hire to sharpen the commercial engine.

Headline numbers and contract wins

Metric	Update
Adjusted EBITDA FY26	Upgraded to not less than £7.0 million (previously £6.0-£7.0 million)
Net debt FY26	Guided to below £6.0 million
Leverage	c.0.85x Net Debt/EBITDA
New business FY26 to date	Exceeds £110 million
Notable awards	DEFRA £39m; NHS England £22m (option to extend to £33m); HMLR uplift £11m to an existing £49m contract

Why the EBITDA upgrade matters

Adjusted EBITDA is a cash‑lite profit measure used to judge operating performance before interest, tax, depreciation and amortisation. Upgrading to not less than £7.0 million signals that cost discipline and contract delivery are tracking ahead of prior expectations. The wording not less than suggests the floor has firmed up rather than a wide range, which normally reads well for confidence.

Leverage of around 0.85x and net debt guided to below £6.0 million put balance sheet risk in a manageable zone for a services business. Lower interest burden and more financial flexibility make it easier to invest in growth without leaning on shareholders.

£110m+ in new business: public sector engine is humming

Total new business secured this year now exceeds £110 million. The standout deals are squarely in TPXimpact’s sweet spot of UK public services, which make up over 90% of its client base:

• Department for Environment, Food and Rural Affairs (DEFRA) – £39 million
• NHS England – £22 million, with an option to extend to £33 million
• HM Land Registry (HMLR) – £11 million uplift to an existing £49 million contract

These are material, multi‑year pieces of work that typically carry good visibility. The NHS option is worth watching – options are not guaranteed, but having one in place gives a potential kicker if performance is strong.

Debt and leverage: quietly de‑risking the story

Net debt below £6.0 million combined with c.0.85x leverage implies the heavy lifting on the turnaround has flowed through to the balance sheet. In plain terms, the company owes less and earns more than it did a year or two ago, which reduces downside risk.

For context, many investors view sub‑1.0x leverage as comfortable for a people‑based consultancy. It does not remove execution risk, but it makes any bumps easier to handle.

Commercial firepower: new Chief Growth Officer

TPXimpact has appointed Emma Broom as Chief Growth Officer, adding senior depth on public sector sales, delivery and strategic account management. That aligns with management’s pivot from stabilise to scale as the turnaround gives way to a new three‑year growth phase.

Sales leadership matters in framework‑driven public sector markets. The right person can help cross‑sell across departments, improve win rates and ensure timely renewals – all incremental drivers that support margins and cash conversion over time.

Strategy: turnaround complete, next three‑year plan incoming

The Board says the three‑year turnaround plan has been successfully concluded, with improvements in profitability and reduced debt. The FY27 budget is being finalised and a comprehensive three‑year plan will set the next chapter of growth.

Investors will want to see how the plan frames organic growth targets, margin progression and capital allocation. Given the contract momentum, clarity on delivery capacity and hiring plans will also be important.

What’s not disclosed and what to watch

• Revenue growth and gross margins – not disclosed. We have profit guidance, but no top‑line or margin mix detail.
• Cash conversion – not disclosed. With public sector clients, working capital is usually predictable, but the update does not quantify cash generation.
• Exact net debt figure – guidance is below £6.0 million rather than a point estimate.
• Timing and phasing of the £110m+ in new business – not disclosed. The spread across FY26 vs FY27 and beyond will matter for forecasts.
• NHS England option – it is an option to extend to £33 million, not yet exercised.

My take: momentum is real, but execution still counts

Positives

• Guidance upgrade to at least £7.0 million adjusted EBITDA – confidence is edging up, not down.
• Healthy new business over £110 million, anchored by blue‑chip public sector clients.
• Leverage around 0.85x and net debt below £6.0 million – risk profile improving.
• Commercial upgrade with a new Chief Growth Officer to drive the next leg.

Watchouts

• Concentration in UK public sector brings policy and budget dependency.
• No disclosure on revenue, margins or cash conversion limits precision on FY26 outcomes.
• Transition from turnaround to growth requires disciplined hiring and delivery to protect margins.

Catalysts to monitor into FY27

• Full FY26 results – detail on revenue, margin mix, cash flow and the exact net debt outcome.
• Update on the NHS England option and further public sector frameworks or extensions.
• Publication of the new three‑year plan – targets for growth, profitability and capital allocation.

Bottom line

This is a clean, confidence‑building update from TPXimpact. A firmer EBITDA floor, lower leverage and chunky public sector wins are the right ingredients as management closes the chapter on turnaround and opens the next one on growth. The numbers we do not yet have – revenue, margins and cash – will decide how far the re‑rating can go, but the direction of travel is positive.